Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
DAPK1 underexpression
Cancer:
Clear Cell Renal Cell Carcinoma
Drug:
Sutent (sunitinib)
(
c-KIT inhibitor
,
VEGFR inhibitor
,
PDGFR inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Aging (Albany NY)
Title:
Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma
Published date:
11/16/2020
Excerpt:
Sunitinib-resistant ccRCC cells show significantly lower DAPK1 mRNA and protein levels than sunitinib-sensitive ccRCC cells.
DOI:
https://doi.org/10.18632/aging.103638
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login